ASTRAZENECA: WAINUA (EPLONTERSEN) GRANTED FIRST-EVER REGULATORY APPROVAL IN THE US FOR THE TREATMENT OF ADULTS WITH POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS
December 22, 2023
December 22, 2023
WILMINGTON, Delaware, Dec. 22 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
US FDA approval based on NEURO-TTRansform Phase III results showing WAINUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life
Additional regulatory reviews underway in rest of world
* * *
AstraZeneca and Ionis' WAINUATM (eplontersen) has been approved in the US f . . .
* * *
US FDA approval based on NEURO-TTRansform Phase III results showing WAINUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life
Additional regulatory reviews underway in rest of world
* * *
AstraZeneca and Ionis' WAINUATM (eplontersen) has been approved in the US f . . .